Skip to main content

About us

The Brain Tumor Biotech Center is an interactive hub for scientists, clinicians and biotech companies in the neuro-oncology space to join forces and accelerate the delivery of novel drugs to patients living with brain tumors.

Neuro-oncology studies brain and spinal cord tumors, which are life-threatening—the median life expectancy for a glioblastoma patient, for example, is 15 months after diagnosis. In most cases of brain cancer, treatment options are largely limited to surgery, radiation and chemotherapy. Feinstein Institutes researchers are working to discover new and better treatments for patients by designing and testing new drugs and drug delivery methods.

The Feinstein Institutes for Medical Research hosted a ribbon cutting ceremony to celebrate the opening of the Brain Tumor Biotech Center, which aims to accelerate treatments to patients who suffer from brain tumors. During the event, a surprise announcement was made that Voices Against Brain Cancer has made a donation of $1 million to the Center.

A progressive and capital-efficient model leveraging the world-class, Feinstein Institutes expertise, the Brain Tumor Biotech Center represents an ideal partner for biotechnology companies as they complete preclinical testing, navigate the regulatory landscape, and execute on clinical development initiatives. As part of Northwell Health, the second largest integrated health system in the country, the Biotech Center is exceptionally placed to interface with the vast patient population and resources of the health system.

Experienced research scientists in the Biotech Center carry out in vitro and in vivo studies using state-of-the-art tools and methodologies, including models for glioblastoma and medulloblastoma. In addition, the Center has experienced Medical Advisory and Investment Advisory Boards that offer both early and late-stage companies expertise in developing a product for market.

The Biotech Center also provides and coordinates the following on-site services:

  • Expedited Internal Review Board and IACUC (IRB link: 
  • Medical writing
  • Grants and contracts 
  • Regulatory (pre-IND, IND, patent, application)
  • Compliance  
  • Technology transfer
  • Clinical research services
  • Clinical trial design and management
  • Data safety monitoring

Meet the team

John Andrew Boockvar, MD

Vice Chair, Department of Neurosurgery , Lenox Hill Hospital

Director, Brain Tumor and Pituitary/ Neuroendocrine Center , Lenox Hill Hospital, Investigator, Laboratory for Brain Tumor Biology , Feinstein Institutes for Medical Research, Professor, Neurosurgery and Otolaryngology/Head and Neck Surgery , Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Marc Symons, PhD

Professor, The Karches Center for Oncology Research, Feinstein Institutes for Medical Research

Co-Director, Brain Tumor Biotech Center, Feinstein Institutes for Medical Research, Director, Light Microscopy Facility, Feinstein Institutes for Medical Research, Professor, Molecular Medicine & Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Brain Tumor Biotech Summit 2019

The 2019 Brain Tumor Biotech Summit will be held on June 7, 2019, at Lenox Hill Hospital in New York City. It brings together the nation’s top cancer specialists and the investment community to promote innovative new therapies for brain tumors. Attendees have the opportunity to network with researchers, oncologists, surgeons, CEOs, hedge fund managers, venture capitalists and leaders in the biotech and pharmaceutical industries. They also receive the latest updates on cancer treatments and learn what’s happening in clinical trials and research labs across the nation.

Presentations will be made by leading financial, pharmaceutical and medical authorities in the field. Keynote speakers include William Curry, MD, co-director of Mass General Neuroscience and Steven Kalkanis, MD, chair of the Department of Neurosurgery and medical director at Henry Ford Cancer Institute.

Click here to view the Brain Tumor Biotech Summit 2019 brochure.

For more information on the event, please contact John Boockvar, MD, director of the Brain Tumor Center at Lenox Hill Hospital or Amanda Amarain, manager of External Relations at Lenox Hill Hospital.

The Brain Tumor Biotech Summit is sponsored by The Feinstein Institutes for Medical Research and The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Advisory Boards

Investment Advisory Board

  • Franklin M. Berger – CFA Managing Director, FMB Research
  • Peter Boockvar – Chief Analyst, The Lindsey Group
  • Adam Goulburn, PhD – Senior Associate, Lux Capital
  • Bruce Leuchter, MD – Credit Suisse
  • Martin Lehr – Associate, Osage University Partners
  • Mark Schoenebaum, MD – Senior Managing Director, ISI Group
  • Jonathan Siegel – Kingdon Capital
  • Desh Govendar – Cedar Lane Enterprises
  • Andrew Schiff, MD MBA – Managing Partner, Aisling Capital
  • Greg Weinhoff – CMI Medical

Medical Advisory Board

  • Marc Symons, PhD – The Feinstein Institutes for Medical Research
  • Henry Friedman, MD – Duke University
  • Linda Liau, MD – UCLA Medical Center
  • Alfredo Quinones-Hinojosa, MD – Johns Hopkins Medical
  • Donald O’Rourke, MD – University of Pennsylvania
  • William Curry, MD – Massachusetts General Hospital
  • David Andrews, MD – Jefferson University Hospital
  • Costas Hadjapanyas, MD – Emory University
  • Howard Fine, MD – New York University
  • Michael Lim, MD – Johns Hopkins Hospital
  • Jeff Raizer, MD – Northwestern University
  • Alexis Demopoulous, MD – Lenox HIll Brain Tumor Center & Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
  • Joseph Landolfi, DO – New Jersey Brain Tumor Center
  • Zvi Ram, MD – Tel Aviv Sourasky Medical Center
  • Andrew Parsa, MD – Northwestern University
  • John Boockvar, MD – Lenox HIll Brain Tumor Center & The Feinstein Institutes for Medical Research
  • Jeff Greenfield, MD – Memorial Sloan Kettering Cancer Center
  • Steve Skirball, MD – Stanford University
  • Rosamaria Ruggieri, PhD – The Feinstein Institutes for Medical Research

Patient Advocacy Board

  • Congressman Patrick Kennedy – One Mind for Research
  • Mario Lichtenstein – Voices Against Brain Cancer
  • Al Musella – Musella Musella Foundation for Brain Tumor Research

Testimonials about the Biotech Center

“The Brain Tumor Biotech Center represents an important step in getting the best minds together to fight this devastating group of diseases. The people involved in this center will help to advance our understanding of brain cancer and this could be highly relevant for a host of other neurological and oncologic diseases.” Congressman Patrick Kennedy – One Mind for Research

“The Brain Tumor Biotech Center team has a proven track record of translating cutting-edge science into clinical-stage drug candidates. It will add significant value to companies developing promising new therapies for patients with brain cancer.” Bruce Leuchter, MD – Director, Healthcare Investment Banking, Credit Suisse

“The Brain Tumor Biotech Center’s medical advisory board composed of international leaders in neurooncology will provide important guidance and leadership for academic researchers and biotech companies who need critical input into drug development, and monitoring and oversight of clinical trials. This novel interface between academia and industry should hasten the translation of biomedical discovery into novel drugs for our patients.” Henry Friedman, MD – Deputy Director, The Preston Robert Tisch Brain Tumor Center at Duke

“Dr. Boockvar and the Brain Tumor Biotech Center helped our company do preclinical work so that we can more quickly move our vaccine into our patients with glioblastoma.” Eric K. Rowinsky, MD – Chief Medical Officer, Stemline Therapeutics, Inc.

“Small biotech companies that I analyze often need an entity like the Brain Tumor Biotech Center to help with regulatory work or clinical trial design. With 2,100 clinical trials under their oversight, the Feinstein Institutes has the expertise and resources to help many of these companies do this more quickly and successfully. Analysts and investors really like this.” Mark Schoenebaum – Senior Managing Director, Biotechnology & Pharmaceuticals, ISI Group

“The Brain Tumor Biotech Center at the Feinstein Institutes is a new concept in the fight against brain cancer. It brings together the experts in the field to work together on this fight; breaking down the barriers to progress that has been slowing down the process. It will surely speed up the search for more effective therapies for this dreadful disease.” Al Musella, DPM – President and Founder, Musella Foundation For Brain Tumor Research & Information, Inc.

“The Brain Tumor Biotech Center helps academic researchers like myself align with biotech companies to move our novel ideas into clinical practice.This has been an often ignored relationship until these entities were started. The Center will continue to foster these important relationships.” Michael Lim, MD – Director of Brain Tumor Immunotherapy, Johns Hopkins Medicine

“On a consistent basis, Dr. Boockvar and his team have exhibited a commitment to brain tumor patients, their families and their caregivers. Our company has collaborated with them via the Brain Tumor Biotech Center and have found their drive, expertise and knowledge, to be unparalleled. We look forward to the Brain Tumor Biotech Center’s continued efforts to bring needed therapies to this important patient population.” Sil Lutkewitte – President, Targepeutics, Inc.

“The Brain Tumor Biotech Center at Feinstein allows investors like myself to interact, vet and follow companies' progress as they move products to market. The Institute is exceptional at helping to overcome beurocratic hurtles and significantly lessens the time it takes companies to cross the translational gap. From an investor's perspective, this is exceedingly important.” Desh Govender – Cedar Lane Enterprises

“Our company recently signed on with the Biotech Center to more rapidly develop a compound of interest for the treatment of glioblastoma. The speed and professionalism of the organization in moving the process along was spectacular and was superior to what is normally seen in standard large academic medical centers. Whether signing confidentiality agreements, material transfer agreements, scientific research agreements or more complicated partnerships and alliances, the Feinstein Institutes has proven to our public company that it is the right partner for us to more quickly and efficiently take our important product to market.” David Brown – Chief Scientific Officer, Novogen

Contact

John A. Boockvar, MD
Co-Director of the Brain Tumor Biotech Center
Phone: (212) 434-3900
Email: [email protected]

Marc Symons, PhD
Co-Director of the Brain Tumor Biotech Center
Phone: (516) 562-1193
Email: [email protected]

Go to top